Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.

@article{Hobernicht2011AcquiredGH,
  title={Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.},
  author={Susan L Hobernicht and Bahareh Michelle Schweiger and P. Zeitler and Miles Wang and Stephen P Hunger},
  journal={Pediatric blood & cancer},
  year={2011},
  volume={56 4},
  pages={671-3}
}
Chronic myelogenous leukemia (CML) is caused by the BCR-ABL1 fusion gene that encodes for a constitutively-active tyrosine kinase. Adults and children with CML are typically treated with imatinib mesylate, a BCR-ABL1 tyrosine kinase inhibitor (TKI), or a second-generation TKI. Several case reports have documented growth delay of unknown mechanism in… CONTINUE READING